For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

ReBoost Nasal Spray has been recalled nationwide after tests found mold and bacteria, prompting FDA warnings of possible ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

The company said some patients had dropped out of the trial because they felt they were losing too much weight.

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

Tirzepatide, used in Mounjaro and Zepbound, can produce dramatic weight loss and improvements in blood pressure, cholesterol ...

Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...

They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.

Under the partnership, Lilly will pay IU up to $40 million to build clinical trial infrastructure, accelerate access to ...

Citi Annual Global Healthcare Conference 2025 December 2, 2025 10:30 AM ESTCompany ParticipantsIlya Yuffa - Executive VP ...